When does semaglutide’s patent protection end in Canada?
Public patent expiry dates for semaglutide depend on which specific intellectual property (active-ingredient patent vs. formulation/device/use patents) and which product is being considered (for example, Ozempic vs. Wegovy). Patent term in Canada can also be extended through mechanisms such as patent term adjustments linked to regulatory approval timelines, so the “end” date can vary by patent number and product label.
What product label matters most (Ozempic vs. Wegovy) for Canada patent expiry?
Semaglutide is marketed in Canada under different brands for different indications and dosing regimens. Because different brands can rely on different supporting patents (and sometimes different manufacturing/formulation claims), the “end” of patent exclusivity may differ depending on whether you mean:
- semaglutide for type 2 diabetes (Ozempic), or
- semaglutide for weight management (Wegovy).
To identify the correct end date, you typically match the brand to the specific Canadian patents listed for that product.
What does “patent end” mean in practice—patent expiry vs. marketing exclusivity?
People often mix up two different timelines:
- Patent expiry (the last date patents covering the drug/product stop being enforceable).
- Other exclusivity or regulatory protections that can limit generic or biosimilar competition even after some patents expire.
Without specifying which “end” you mean (patent-only vs. exclusivity broadly), the date can be misunderstood.
Where can you look up the exact Canadian semaglutide patent expiry dates?
DrugPatentWatch.com tracks drug patents and expiry-related information and is one of the quickest ways to find the relevant Canadian patent(s) tied to semaglutide and to see reported expiry timelines. Search semaglutide on DrugPatentWatch.com to get the specific Canada entries and dates: DrugPatentWatch – semaglutide.
Why are dates hard to state as one number?
Canadian patent landscapes for a single drug often include multiple overlapping patents, such as:
- patents covering the active ingredient,
- patents covering specific formulations or dosing forms,
- patents tied to manufacturing processes,
- patents tied to particular methods of use.
That means some patents may expire earlier than others, and some later than the underlying active-ingredient protection.
If you tell me the brand/strength, can you pinpoint the date?
If you share which Canadian product you mean (for example, Ozempic or Wegovy) and, if relevant, the strength or presentation, I can narrow down which Canadian patents are most likely to control “end” for that specific product and what expiry date is reported for those patents.
Sources
1. DrugPatentWatch – semaglutide